Cargando…
The Incremental Prognostic Value of Hepatocyte Growth Factor in First-Ever Acute Ischemic Stroke: An Early Link Between Growth Factor and Interleukins
Hepatocyte growth factor (HGF) is a potential prognostic factor for acute ischemic stroke (AIS). In this study, we sought to validate its earlier predictive accuracy within 24 h for first-ever AIS. Moreover, as HGF interacts with interleukins, their associations may lead to novel immunomodulatory th...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371202/ https://www.ncbi.nlm.nih.gov/pubmed/34421795 http://dx.doi.org/10.3389/fneur.2021.691886 |
_version_ | 1783739591737475072 |
---|---|
author | Li, Fangfang Liu, Ping Huang, Yuyou Li, Lingzhi Zhang, Sijia Yang, Zhenhong Wang, Rongliang Tao, Zhen Han, Ziping Fan, Junfen Zheng, Yangmin Zhao, Haiping Luo, Yumin |
author_facet | Li, Fangfang Liu, Ping Huang, Yuyou Li, Lingzhi Zhang, Sijia Yang, Zhenhong Wang, Rongliang Tao, Zhen Han, Ziping Fan, Junfen Zheng, Yangmin Zhao, Haiping Luo, Yumin |
author_sort | Li, Fangfang |
collection | PubMed |
description | Hepatocyte growth factor (HGF) is a potential prognostic factor for acute ischemic stroke (AIS). In this study, we sought to validate its earlier predictive accuracy within 24 h for first-ever AIS. Moreover, as HGF interacts with interleukins, their associations may lead to novel immunomodulatory therapeutic strategies. Patients with first-ever AIS (n = 202) within 24 h were recruited. Plasma HGF and related interleukin concentrations were measured by multiplex immunoassays. The primary and secondary outcomes were major disability (modified Rankin scale score ≥3) at 3 months after AIS and death, respectively. Elastic net regression was applied to screen variables associated with stroke outcome; binary multivariable logistic analysis was then used to explore the relationship between HGF level and stroke outcome. After multivariate adjustment, upregulated HGF levels were associated with an increased risk of the primary outcome (odds ratio, 7.606; 95% confidence interval, 3.090–18.726; p < 0.001). Adding HGF to conventional risk factors significantly improved the predictive power for unfavorable outcomes (continuous net reclassification improvement 37.13%, p < 0.001; integrated discrimination improvement 8.71%, p < 0.001). The area under the receiver operating characteristic curve value of the traditional model was 0.8896 and reached 0.9210 when HGF was introduced into the model. An elevated HGF level may also be a risk factor for mortality within 3 months poststroke. The HGF level was also positively correlated with IL-10 and IL-16 levels, and HGF before interaction with all interleukins was markedly negatively correlated with the lymphocyte/neutrophil ratio. HGF within 24 h may have prognostic potential for AIS. Our findings reinforce the link between HGF and interleukins. |
format | Online Article Text |
id | pubmed-8371202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83712022021-08-19 The Incremental Prognostic Value of Hepatocyte Growth Factor in First-Ever Acute Ischemic Stroke: An Early Link Between Growth Factor and Interleukins Li, Fangfang Liu, Ping Huang, Yuyou Li, Lingzhi Zhang, Sijia Yang, Zhenhong Wang, Rongliang Tao, Zhen Han, Ziping Fan, Junfen Zheng, Yangmin Zhao, Haiping Luo, Yumin Front Neurol Neurology Hepatocyte growth factor (HGF) is a potential prognostic factor for acute ischemic stroke (AIS). In this study, we sought to validate its earlier predictive accuracy within 24 h for first-ever AIS. Moreover, as HGF interacts with interleukins, their associations may lead to novel immunomodulatory therapeutic strategies. Patients with first-ever AIS (n = 202) within 24 h were recruited. Plasma HGF and related interleukin concentrations were measured by multiplex immunoassays. The primary and secondary outcomes were major disability (modified Rankin scale score ≥3) at 3 months after AIS and death, respectively. Elastic net regression was applied to screen variables associated with stroke outcome; binary multivariable logistic analysis was then used to explore the relationship between HGF level and stroke outcome. After multivariate adjustment, upregulated HGF levels were associated with an increased risk of the primary outcome (odds ratio, 7.606; 95% confidence interval, 3.090–18.726; p < 0.001). Adding HGF to conventional risk factors significantly improved the predictive power for unfavorable outcomes (continuous net reclassification improvement 37.13%, p < 0.001; integrated discrimination improvement 8.71%, p < 0.001). The area under the receiver operating characteristic curve value of the traditional model was 0.8896 and reached 0.9210 when HGF was introduced into the model. An elevated HGF level may also be a risk factor for mortality within 3 months poststroke. The HGF level was also positively correlated with IL-10 and IL-16 levels, and HGF before interaction with all interleukins was markedly negatively correlated with the lymphocyte/neutrophil ratio. HGF within 24 h may have prognostic potential for AIS. Our findings reinforce the link between HGF and interleukins. Frontiers Media S.A. 2021-08-04 /pmc/articles/PMC8371202/ /pubmed/34421795 http://dx.doi.org/10.3389/fneur.2021.691886 Text en Copyright © 2021 Li, Liu, Huang, Li, Zhang, Yang, Wang, Tao, Han, Fan, Zheng, Zhao and Luo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Li, Fangfang Liu, Ping Huang, Yuyou Li, Lingzhi Zhang, Sijia Yang, Zhenhong Wang, Rongliang Tao, Zhen Han, Ziping Fan, Junfen Zheng, Yangmin Zhao, Haiping Luo, Yumin The Incremental Prognostic Value of Hepatocyte Growth Factor in First-Ever Acute Ischemic Stroke: An Early Link Between Growth Factor and Interleukins |
title | The Incremental Prognostic Value of Hepatocyte Growth Factor in First-Ever Acute Ischemic Stroke: An Early Link Between Growth Factor and Interleukins |
title_full | The Incremental Prognostic Value of Hepatocyte Growth Factor in First-Ever Acute Ischemic Stroke: An Early Link Between Growth Factor and Interleukins |
title_fullStr | The Incremental Prognostic Value of Hepatocyte Growth Factor in First-Ever Acute Ischemic Stroke: An Early Link Between Growth Factor and Interleukins |
title_full_unstemmed | The Incremental Prognostic Value of Hepatocyte Growth Factor in First-Ever Acute Ischemic Stroke: An Early Link Between Growth Factor and Interleukins |
title_short | The Incremental Prognostic Value of Hepatocyte Growth Factor in First-Ever Acute Ischemic Stroke: An Early Link Between Growth Factor and Interleukins |
title_sort | incremental prognostic value of hepatocyte growth factor in first-ever acute ischemic stroke: an early link between growth factor and interleukins |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371202/ https://www.ncbi.nlm.nih.gov/pubmed/34421795 http://dx.doi.org/10.3389/fneur.2021.691886 |
work_keys_str_mv | AT lifangfang theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT liuping theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT huangyuyou theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT lilingzhi theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT zhangsijia theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT yangzhenhong theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT wangrongliang theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT taozhen theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT hanziping theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT fanjunfen theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT zhengyangmin theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT zhaohaiping theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT luoyumin theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT lifangfang incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT liuping incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT huangyuyou incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT lilingzhi incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT zhangsijia incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT yangzhenhong incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT wangrongliang incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT taozhen incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT hanziping incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT fanjunfen incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT zhengyangmin incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT zhaohaiping incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins AT luoyumin incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins |